CORD-19:e847d433e7424152a9846673209cb73027415ecd / 2258-2529 JSONTXT

{"project":"CORD-PICO","denotations":[{"id":"p1_all4","span":{"begin":0,"end":271},"obj":"Intervention"},{"id":"p2_i2","span":{"begin":28,"end":47},"obj":"Pharmacological"}],"text":"nalidixic acid (NAL) and to ciprofloxacin (CIP); Group 2 (26 E. coli and 34 non-E. coli): NAL-resistant (R), and with MIC of CIP ranging 0.5-2 mg/l; Group 3: (28 E. coli and 22 non-E. coli): NAL-R and CIP-R. W/A testing was done with Combo Urine 1S panels, containing NAL"}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T2","span":{"begin":240,"end":245},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0001088"}],"text":"nalidixic acid (NAL) and to ciprofloxacin (CIP); Group 2 (26 E. coli and 34 non-E. coli): NAL-resistant (R), and with MIC of CIP ranging 0.5-2 mg/l; Group 3: (28 E. coli and 22 non-E. coli): NAL-R and CIP-R. W/A testing was done with Combo Urine 1S panels, containing NAL"}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T6","span":{"begin":43,"end":46},"obj":"Disease"},{"id":"T8","span":{"begin":125,"end":128},"obj":"Disease"},{"id":"T10","span":{"begin":201,"end":204},"obj":"Disease"},{"id":"T13998","span":{"begin":43,"end":46},"obj":"Disease"},{"id":"T1921","span":{"begin":125,"end":128},"obj":"Disease"},{"id":"T53778","span":{"begin":201,"end":204},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0009459"},{"id":"A7","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0015364"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0009459"},{"id":"A9","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0015364"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0009459"},{"id":"A11","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0015364"},{"id":"A92058","pred":"mondo_id","subj":"T13998","obj":"http://purl.obolibrary.org/obo/MONDO_0009459"},{"id":"A12452","pred":"mondo_id","subj":"T13998","obj":"http://purl.obolibrary.org/obo/MONDO_0015364"},{"id":"A19401","pred":"mondo_id","subj":"T1921","obj":"http://purl.obolibrary.org/obo/MONDO_0009459"},{"id":"A10800","pred":"mondo_id","subj":"T1921","obj":"http://purl.obolibrary.org/obo/MONDO_0015364"},{"id":"A34459","pred":"mondo_id","subj":"T53778","obj":"http://purl.obolibrary.org/obo/MONDO_0009459"},{"id":"A19944","pred":"mondo_id","subj":"T53778","obj":"http://purl.obolibrary.org/obo/MONDO_0015364"}],"text":"nalidixic acid (NAL) and to ciprofloxacin (CIP); Group 2 (26 E. coli and 34 non-E. coli): NAL-resistant (R), and with MIC of CIP ranging 0.5-2 mg/l; Group 3: (28 E. coli and 22 non-E. coli): NAL-R and CIP-R. W/A testing was done with Combo Urine 1S panels, containing NAL"}